Geron (GERN) Return on Capital Employed (2011 - 2026)
Geron (GERN) posted Return on Capital Employed of 10.8% for Q1 2026, up 27.95% sequentially from 14.99% in Q4 2025, and up 1527.0% YoY from 0.66% in Q1 2025.
Geron (GERN) Return on Capital Employed (2011 - 2026) Analysis & Trends
Geron has reported Return on Capital Employed for 16 years, with the latest figure at 10.8% in Q1 2026.
- Quarterly Return on Capital Employed rose 1527.0% year-over-year to 10.8% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10.8% (up 1527.0% YoY) and the FY2025 annual result came in at 14.57%, up 2826.0% from the prior year.
- Return on Capital Employed climbed to 10.8% in Q1 2026 per GERN's latest filing, from 14.99% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 10.8% in Q1 2026 and troughed at 102.71% in Q4 2022.
- A 5-year average of 51.04% and a median of 56.85% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed tumbled 4009 bps in 2022, then jumped 5393 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 102.71% in 2022, then jumped by 36 bps to 65.64% in 2023, then jumped by 39 bps to 40.3% in 2024, then jumped by 63 bps to 14.99% in 2025, then grew by 28 bps to 10.8% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 10.8%, 14.99%, and 13.32% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | -11.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.35% |
| Mar 31, 2026 | -10.80% |
| Dec 31, 2025 | -14.99% |
| Sep 30, 2025 | -13.32% |
| Jun 30, 2025 | -15.66% |
| Mar 31, 2025 | -26.07% |
| Dec 31, 2024 | -40.30% |
| Sep 30, 2024 | -67.25% |
| Jun 30, 2024 | -62.77% |
| Mar 31, 2024 | -66.68% |
| Dec 31, 2023 | -65.64% |
| Sep 30, 2023 | -55.92% |
| Jun 30, 2023 | -50.05% |
| Mar 31, 2023 | -56.85% |
| Dec 31, 2022 | -102.71% |
| Sep 30, 2022 | -83.62% |
| Jun 30, 2022 | -66.10% |
| Mar 31, 2022 | -68.97% |
| Dec 31, 2021 | -62.62% |
| Sep 30, 2021 | -52.57% |